|
The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic |
Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctot KL |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctot KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. Journal of Medical Economics 2009; 12(4): 361-370 Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal /administration & Antibodies, Monoclonal, Humanized; Antiviral Agents /administration & Canada /epidemiology; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Infant; Inuits /statistics & Male; Nunavut /epidemiology; Palivizumab; Quality-Adjusted Life Years; Respiratory Syncytial Virus Infections /drug therapy /economics /ethnology /prevention & control; dosage /economics; dosage /economics; numerical data AccessionNumber 22010000358 Date bibliographic record published 18/12/2012 |
|
|
|